experience with tadalafil in pediatric pulmonary arterial hypertension Pediatr Cardiol 2013;33(5):683–688 116 Kang KK, Ahn GJ, Sohn YS, et al DA-8159, a potent cGMP phosphodiesterase inhibitor, attenuates monocrotaline-induced pulmonary hypertension in rats Arch Pharm Res 2003;26:612–619 117 Corbin J, Rannels S, Neal D, et al Sildenafil citrate does not affect cardiac contractility in human or dog heart Curr Med Res Opin 2003;19:747–752 118 Cremers B, Scheler M, Maack C, et al Effects of sildenafil (viagra) on human myocardial contractility, in vitro arrhythmias, and tension of internal mammaria arteries and saphenous veins J Cardiovasc Pharmacol 2003;41:734–743 119 Sugiyama A, Satoh Y, Shiina H, et al Cardiac electrophysiologic and hemodynamic effects of sildenafil, a PDE5 inhibitor, in anesthetized dogs J Cardiovasc Pharmacol 2001;38:940– 946 120 Barst RJ, Langleben D, Frost A, et al Sitaxsentan therapy for pulmonary arterial hypertension Am J Respir Crit Care Med 2004;169:441–447 121 Barst RJ, McGoon M, McLaughlin V, et al Beraprost therapy for pulmonary arterial hypertension J Am Coll Cardiol 2003;41:2119– 2125 122 Ghofrani HA, Reichenberger F, Kohstall MG, et al Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial Ann Intern Med 2004;141:169–177 123 Humbert M, Barst RJ, Robbins IM, et al Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 Eur Respir J 2004;24:353–359 124 McLaughlin VV, Oudiz RJ, Frost A, et al Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension Am J Respir Crit Care Med 2006;174:1257–1263 125 Rubin LJ, Badesch DB, Barst RJ, et al Bosentan therapy for pulmonary arterial hypertension N Engl J Med 2002;346:896–903 126 Simonneau G, Barst RJ, Galie N, et al Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a doubleblind, randomized, placebo-controlled trial Am J Respir Crit Care Med 2002;165:800–804 127 Paul GA, Gibbs JS, Boobis AR, et al Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension Br J Clin Pharmacol 2005;60:107–112 128 McLaughlin VV, Shillington A, Rich S Survival in primary pulmonary hypertension: the impact of epoprostenol therapy Circulation 2002;106:1477–1482 129 Sitbon O, Humbert M, Nunes H, et al Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival J Am Coll Cardiol 2002;40:780–788 130 Micheletti A, Hislop AA, Lammers A, et al Role of atrial septostomy in the treatment of children with pulmonary arterial hypertension Heart 2006;92:969–972 131 Kerstein D, Levy PS, Hsu DT, et al Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension Circulation 1995;91:2028–2035 132 Kurzyna M, Dabrowski M, Bielecki D, et al Atrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertension Chest 2007;131:977–983 133 Blanc J, Vouhe P, Bonnet D Potts shunt in patients with pulmonary hypertension N Engl J Med 2004;350:623